Vivo Capital — 2020 Investments
5 investments dated 2020 · listed companies and verified rows first · show all
Mereo BioPharma is a biopharmaceutical company that develops novel therapies for rare diseases with limited or no treatment options, focusing on lead programs in osteogenesis imperfecta (OI) and Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD).
BiotechLondon
John Richard(Head of Corporate Development and Co-Founder)Dr. Denise Scots-Knight(Chief Executive Officer and Co-Founder)Charles Sermon(General Counsel and Co-Founder)Richard Jones(Chief Financial Officer)Jill Henrich(Senior Vice President)
BoardDr. Deepa Pakianathan(Non-Executive Director)
Co-investorsPontifax Venture Capital
Houston, US
Board seatJoseph Siletto· per SEC Form D · $45M raise · filed Jul 2020
Plano, US
Board seatJack Nielsen· per SEC Form D · $50M raise · filed Jun 2020
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.
BiotechHealthtechMedfield, US
Roger Heerman(Chief Business/Operating Officer / Co-Founder)Frazer Morgan(Chief Development Officer / Co-Founder)Robert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)
Co-investors5AM VenturesAtlas VentureRA CapitalEQT Life SciencesSixty Degree CapitalGimv+1 more
Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program.
BiotechHealthtechFoster City, US
Mark Vignola, Ph.D.(Executive Officer)Bryan Yoon(Executive Officer)Senthil Sundaram(Director, Executive Officer)Weidong Zhong, Ph.D.(Executive Officer, Director)Jill Quigley(Director)David Fellows(Director)
Co-investorsDecheng CapitalLAVLilly Asia Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.